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RNA interference is triggered by double-stranded RNA that is processed into small interfering RNAs (siRNAs) by Dicer
enzyme. Endogenously, RNA interference triggers are created from small noncoding RNAs called microRNAs (miRNAs).
RNA-induced silencing complexes (RISC) in human cells can be programmed by exogenously introduced siRNA or
endogenously expressed miRNA. siRNA-programmed RISC (siRISC) silences expression by cleaving a perfectly
complementary target mRNA, whereas miRNA-induced silencing complexes (miRISC) inhibits translation by binding
imperfectly matched sequences in the 39 UTR of target mRNA. Both RISCs contain Argonaute2 (Ago2), which catalyzes
target mRNA cleavage by siRISC and localizes to cytoplasmic mRNA processing bodies (P-bodies). Here, we show that
RCK/p54, a DEAD box helicase, interacts with argonaute proteins, Ago1 and Ago2, in affinity-purified active siRISC or
miRISC from human cells; directly interacts with Ago1 and Ago2 in vivo, facilitates formation of P-bodies, and is a
general repressor of translation. Disrupting P-bodies by depleting Lsm1 did not affect RCK/p54 interactions with
argonaute proteins and its function in miRNA-mediated translation repression. Depletion of RCK/p54 disrupted P-
bodies and dispersed Ago2 throughout the cytoplasm but did not significantly affect siRNA-mediated RNA functions of
RISC. Depleting RCK/p54 released general, miRNA-induced, and let-7-mediated translational repression. Therefore, we
propose that translation repression is mediated by miRISC via RCK/p54 and its specificity is dictated by the miRNA
sequence binding multiple copies of miRISC to complementary 39 UTR sites in the target mRNA. These studies also
suggest that translation suppression by miRISC does not require P-body structures, and location of miRISC to P-bodies
is the consequence of translation repression.
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Introduction
Small non-coding RNAs play important roles in the
posttranscriptional regulation of genes that code for diverse
biological functions, e.g., in most metazoan organisms from
nematodes to mammals [1–3]. Two classes of such small (; 21
nucleotide [nt]) RNAs that have been extensively studied in
gene silencing are short interfering RNAs (siRNAs) and
microRNAs (miRNAs) (reviewed in [4]). Currently, the best
known mechanism of gene silencing is RNA interference
(RNAi), an evolutionarily conserved process whereby double-
stranded RNA induces the sequence-speciﬁc degradation of
homologous mRNA [5]. Long double-stranded RNA and
precursors of miRNAs are processed by Dicer enzyme, and
siRNAs are assembled into an RNA-induced silencing com-
plex called RISC. The RNAi machinery can also be pro-
grammed in cells by introducing duplexes of siRNAs that are
assembled into RNA-induced silencing complexes (siRISC)
containing Dicer, argonautes, and other proteins [6].
Although RNAi has commonly been associated with siRNAs,
this process is largely mediated in plants by miRNAs [7,8], and
examples of miRNA-mediated RNAi have been found in
mammals and viruses (reviewed in [6]). Growing evidence
indicates that miRNAs are important in human disease,
including cancers [9–12]. For example, relatively low levels of
let-7 miRNA up-regulate RAS protein in lung cancer cells,
demonstrating a possible role of miRNA in tumorigenesis
[13].
Both classes of small RNAs are assembled into silencing
complexes that contain Dicer, argonautes, and other proteins
[4], but they silence gene expression by two different
pathways. Upon recognizing complementary mRNA, acti-
vated RISC forms an effector complex with the target mRNA
[6]. Antisense siRNA in activated RISC serves as a guide for
Argonaute2 (Ago2) [14–16] to catalyze the cleavage of target
mRNA at a site ; 10 nt from the 59 end of the siRNA [17].
Following cleavage, the target mRNA is degraded. Activated
RISC, as a multi-turnover enzyme [18], is recycled to cleave
additional mRNA targets.
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PLoS BIOLOGYIn the case of miRNAs, they are assembled into miRNA-
induced silencing complexes (miRISC) that contain Dicer,
argonaute proteins, transactivation-responsive RNA-binding
protein [19–22], and other cellular factors [4]. This assembly
into miRISC has been implicated in miRNA functions [19–
24].
Whether siRNA-mediated RNAi or miRNA-mediated in-
hibition of translation is triggered depends largely on the
degree of complementarity between the siRNA or miRNA
and its mRNA target (reviewed in [2,25]). While both miRNAs
and siRNAs must harbor sequences that recognize the target
mRNA, miRNAs are generally not fully complementary to the
mRNA target. In contrast, siRNA sequences must be
completely complementary to the mRNA target cleavage site
to efﬁciently induce cleavage through the RNAi pathway.
Interestingly, miRNAs can behave like siRNAs and induce
mRNA cleavage when the miRNA sequence is completely
complementary to a target mRNA [18,26,27].
In human cells, the mechanism by which the endogenous
miRNA and siRNA pathways are distinguished is not clearly
understood. It is also unclear how miRNAs repress the
translation of target mRNAs. New insights into miRNA
function have recently been provided by localization of the
RISC components, Ago1 and Ago2, in mRNA-processing
bodies (P-bodies) [28–31], which are cytoplasmic foci contain-
ing translationally repressed mRNP complexes. During
cellular translational control, an mRNP complex is formed
containing the translationally repressed mRNA and associated
repressor proteins and lacking translation initiation factors
[32]. These translationally repressed mRNPs accumulate in P-
bodies and contain proteins that mediate the translation [33–
35], RNAi [28–31,36], translation suppression [37], and decay
[32,38] of cellular mRNA. P-bodies, also referred to as GW or
Dcp bodies, contain GW182 proteins that have recently been
reported to play a role in RNAi [39–41]. Other proteins found
in cytoplasmic P-bodies and implicated in mRNA processing
are RCK/p54, Lsm1, Dcp1:2, and eIF4E [32,33,38]. Given that
target mRNA and RISC components have been co-localized in
P-bodies [29,31], it is possible that P-bodies are the bona ﬁde
site for RISC-induced target cleavage or repression of trans-
lation. However, the mechanism by which target mRNA and
miRISC are directed to P-bodies and how translation is
repressed by miRISC is still unknown.
One P-body protein, RCK/p54, the human homolog of yeast
Dhh1p, is a member of the ATP-dependent DEAD box
helicase family and was originally identiﬁed as a proto-
oncogene [42]. In human cells, RCK/p54 interacts in P-bodies
with the translation initiation factor, eIF4E [33]. The Xenopus
homolog of RCK/p54, Xp54, which interacts with eIF4E and
forms RNA-dependent oligomers, represses the translation of
mRNA in oocytes and eggs [43]. In yeast, Dhh1p interacts with
the decapping and deadenylase complex and functions in
translational repression [44]. Dhh1p has also recently been
shown to stimulate translational repression by inhibiting
production of the pre-initiation complex [45].
Here, we show that RCK/p54 interacts with argonaute
proteins, Ago1 and Ago2, in afﬁnity-puriﬁed active RISC
assemblies from human cells programmed with siRNA or
endogenous miRNA; directly interacts with Ago1 and Ago2 in
vivo, facilitates formation of cytoplasmic P-bodies, and acts as
a general repressor of translation. Depletion of RCK/p54
disrupted P-bodies and dispersed Ago2 throughout the
cytoplasm. We further show that depletion of RCK/p54 did
not signiﬁcantly affect the RNAi function of RISC, but
released general, miRNA-induced and let-7-mediated trans-
lational repression. Taken together, our results suggest that
RCK/p54 is the effector molecule in miRISC that represses
translation and that the speciﬁcity of this repression is
dictated by the sequence of miRNA binding to complemen-
tary sites in the 39 UTR of the target mRNA.
Results
Human Argonaute Proteins Interact with RCK/p54, a
Component of P-Bodies
To investigate the mechanism of miRNA-mediated repres-
sion of mRNA translation and to determine the interactions
of P-body components with the RNAi machinery, we
constructed expression vectors for the yellow ﬂuorescent
protein (YFP)-tagged P-body proteins, Lsm1, RCK/p54, Dcp2,
and eIF4E. These vectors were co-expressed in HeLa cells
with Myc-tagged Ago2 and immunopuriﬁed using anti-Myc
antibodies. The protein composition of isolated complexes
was analyzed by immunoblot using antibodies against green
ﬂuorescent protein (GFP) or Myc. When total cell extracts
(TCE) were analyzed to determine the protein expression
efﬁciencies of the vectors used in these experiments (Figure
1A, TCE lane), all YFP- and Myc-tagged proteins were
expressed. Analysis of immunopuriﬁed complexes revealed
that Ago1, Dcp2, RCK/p54, and eIF4E formed complexes with
Ago2 (Figure 1A, anti-Myc lane). Control experiments showed
that YFP did not co-purify with Ago2 (Figure 1A). Interest-
ingly, Lsm1 did not co-purify with Ago2, but localized to P-
body structures in HeLa cells (Figure 1B).
Since P-bodies contain RNA and proteins, many protein
components of P-bodies are likely to be assembled on a
common RNA scaffold without forming functional protein–
protein interactions. To address this possibility, HeLa cells
were transfected with vectors to co-express Myc-Ago2 and the
YFP-tagged P-body proteins, Lsm1, RCK/p54, Dcp2, and
eIF4E, subjected to RNase A digestion, and immunopuriﬁed.
Analysis of immunopuriﬁed complexes showed that Ago1 and
RCK/p54 interactions with Myc-Ago2 were not affected by
RNase treatment, whereas the amounts of Dcp2 and eIF4E
protein that co-puriﬁed with Myc-Ago2 decreased signiﬁ-
cantly (Figure 1A, anti-Myc lane). Control experiments
analyzing Myc-Ago2 showed that equal amounts of complexes
were puriﬁed (Figure 1A, anti-Myc lane). Taken together,
these results suggest that Ago1 and RCK/p54 directly
interacted with Ago2, whereas Dcp2 and eIF4E interactions
with Ago2 were RNA-mediated. These results do not rule out
the possibility that Ago1 and RCK/p54 interactions with Ago2
were mediated by adapter protein(s).
Cytoplasmic P-bodies contain RCK/p54, Lsm1, Dcp2, and
eIF4E [32,33,38]. To conﬁrm whether these structures also
contain Ago2 as recently reported [28,31], we transfected
HeLa cells with expression vectors containing YFP-Ago1, CFP
(cyan ﬂuorescent protein)-Ago1, YFP-Ago2, and CFP-Ago2.
Transiently expressed YFP- and CFP-tagged Ago1 and Ago2
co-localized at speciﬁc foci in cytoplasm (unpublished data).
To examine the contents of these cytoplasmic foci, HeLa cells
were transfected with expression vectors for YFP-Lsm1 and
CFP-Ago2, or YFP-RCK/p54 and CFP-Ago2, and visualized 24
h later by confocal microscopy. As shown in Figure 1B, CFP-
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bona ﬁde P-body proteins [32,33,38]. In addition, immuno-
ﬂuorescence experiments showed that endogenous Ago2 co-
localized with Lsm1 in P-bodies (Figure S1). Interestingly,
over-expressing YFP-RCK/p54 increased the average number
of P-bodies in every cell (Figure 1B, compare a and d). To
conﬁrm that the localization of Ago2 and Lsm1 to P-bodies
was not the result of over-expression in transiently trans-
fected cells, we immunostained cells with antibodies to
endogenous Ago2 and Lsm1 and found that the localization
Figure 1. Human Argonaute Proteins Interact with RCK/p54, a Component of P-Bodies
(A) Immunoprecipitation and immunoblot analyses. TCEs from HeLa cells co-expressing Myc-Ago2 and YFP-Ago1, YFP-Dcp2, YFP-RCK/p54, YFP-eIF4E,
YFP-Lsm1, or YFP were treated with þ/  RNase A followed by Myc-Ago2 immunoprecipitation. TCE and anti-Myc IPs were analyzed by immunoblot
using anti-GFP and anti-Myc antibodies.
(B) In vivo localization of RCK/p54 and Ago2 to P-bodies. HeLa cells expressing YFP-Lsm1 and CFP-Ago2 (a, b, and c), YFP-RCK/p54 and CFP-Ago2 (d, e,
and f) were visualized by confocal microscopy at 24 h post-transfection.
(C) Visualization of interactions between RCK/p54 and Ago2 in P-bodies by FRET. HeLa cells expressing YFP-RCK/p54 and CFP-Ago2 were fixed at 24 h
post-transfection. FRET was measured by an acceptor photobleaching method. Fluorescence images of donor (CFP-Ago2) and acceptor (YFP-RCK/p54)
molecules were taken before and after photobleaching YFP. FRET efficiencies were calculated as described [48,49,68], and data were analyzed by Leica
confocal software. Arrows point to P-bodies, which are enlarged in insets.
(D) FRET efficiencies between different P-body protein donor: acceptor pairs. HeLa cells co-expressing YFP-RCK/p54 and CFP-Ago2, YFP-Lsm1 and CFP-
Ago2, YFP-RCK/p54 and CFP, YFP-Ago1 and CFP-Ago2, YFP-Ago2 and CFP-Ago1, YFP-RCK/p54 and CFP-Ago-1, as well as YFP-Ago1 and CFP, were fixed
and FRET efficiencies were measured.
DOI: 10.1371/journal.pbio.0040210.g001
PLoS Biology | www.plosbiology.org July 2006 | Volume 4 | Issue 7 | e210 1124
Translational Repression by Human RISCof Ago2 and Lsm1 to P-bodies (Figure S1) was similar to that
in Figure 1B. These results show that Ago2, Lsm1, and RCK/
p54 are present in P-bodies.
To visualize protein–protein interactions in vivo, we used
ﬂuorescence resonance energy transfer (FRET) as a probe. In
FRET, a ﬂuorescent donor molecule transfers energy via a
nonradiative dipole–dipole interaction to an acceptor mole-
cule [46]. We used a well-known donor: acceptor ﬂuorescent-
protein pair, CFP:YFP, with a Fo ¨rster distance (R0) of 4.9 nm
[47]. To determine whether Ago1 and Ago2 interacted in vivo
with each other and with RCK/p54, we measured the FRET
efﬁciency between the donor, CFP-Ago2, and acceptor, YFP-
RCK/p54.Todoso,weusedamethodinwhichthedonorsignal
lost during FRET is restored by deliberately photobleaching
the acceptor ﬂuorophore to abolish its capacity as an energy
acceptor [48–50]. In cells expressing YFP-RCK/p54 and CFP-
Ago2,theFRET efﬁciency was 21.07% 62.52% (Figure 1Cand
1D). In cells expressing CFP-Ago2 and YFP-Lsm1, FRET
efﬁciency was not signiﬁcant (1.62% 6 1.11%), corroborating
our immunoprecipitation results (Figure 1A). Furthermore,
cells co-expressing YFP-RCK/p54 and CFP showed no signiﬁ-
cant FRET efﬁciency (1.64% 6 1.28%). Similar to the YFP-
RCK/p54 and CFP-Ago2 pair, YFP-Ago1 and CFP-Ago2
showed an efﬁcient FRET (19.61% 6 4.51%), indicating a
direct interaction between Ago1 and Ago2 in vivo [28].
Interestingly, the FRET efﬁciency between Ago1 and Ago2
decreased to 12.13% 6 1.6% when we used CFP-Ago1 and
YFP-Ago2, indicating that the energy transfer efﬁciencies
were sensitive to the orientation of donor: acceptor pair in
the ribonucleoprotein (RNP) complex. Moreover, only
moderate energy transfer efﬁciency (6.41% 6 1.96%) was
seen when YFP-RCK/p54 and CFP-Ago1 were used in FRET
experiments, suggesting that this donor: acceptor pair was
not as ideally oriented for an efﬁcient energy transfer as the
pair CFP-Ago1 and YFP-Ago2. Alternatively, RCK/p54-Ago1-
Ago2 is assembled in an RNP complex where the donor:
acceptor pair is affected by the location of the probe.
Nonetheless, the efﬁciency of energy transfer was well above
the background control (0.99%). As a control experiment,
cells co-expressing YFP-Ago1 and CFP showed no signiﬁcant
FRET efﬁciency (0.99% 6 0.67%). Taken together, these
results indicate that Ago1 and Ago2 directly interact in vivo
with each other and with RCK/p54.
RCK/p54 Is a Component of RISC Containing the Guide
Strand of siRNA
To determine whether RCK/p54 is recruited into a func-
tional RISC complex containing argonaute proteins or its
association with Ago1/Ago2 is merely due to their co-
localization in P-bodies, we afﬁnity-puriﬁed active RISCs,
analyzed their protein composition, and assayed for RISC
function (Figure 2A). siRNA duplexes targeting GFP (siGFP)
were synthesized and 39 -biotin moieties were conjugated to
the 39 -end of the guide strand. These two duplexes
(unmodiﬁed siGFP and biotin-modiﬁed siGFP) were trans-
fected into HeLa cells, and RISCs were captured by
incubating cell extracts with streptavidin-conjugated mag-
netic beads [51,52]. Beads and supernatants were analyzed for
RISC function, i.e., the ability to cleave target mRNA in vitro
[53]. RISCs primed with siGFP or biotin-modiﬁed siGFP guide
strands efﬁciently cleaved their target mRNA (Figure 2B,
lanes 1 and 3), but only biotin-containing RISC puriﬁed on
streptavidin-magnetic beads showed cleavage activity (Figure
2B, lanes 2 and 4). These results show that active RISC can be
programmed in human cells by biotin-containing guide
strands of siRNAs and can be captured on magnetic beads
for further analysis.
To probe the involvement of P-body proteins in this
puriﬁed active RISC, its protein composition was analyzed by
immunoblot using antibodies against Flag tag or endogenous
Ago2, RCK/p54, eIF4E, and Lsm1. When the RNAi machinery
was primed with biotin-containing siRNAs, Ago1, Ago2, and
RCK/p54 were co-puriﬁed with RISC; and when the guide
strand of siRNA did not contain biotin, RISC did not bind to
beads (Figure 2C). Interestingly, eIF4E did not co-purify with
Figure 2. Isolation of Active Human RISC Containing RCK/p54-Ago1/
Ago2
(A) Experimental outline to purify active human RISC. The guide strands
of siRNA complexes targeting GFP (si-GFP) were conjugated with 39
biotin (si-GFP-Bi; blue strands) and transfected into HeLa cells. RISCs were
captured by incubating cell extracts with streptavidin-magnetic beads.
(B) Target mRNA is cleaved by biotin-captured RISC. Bead (B) and
supernatant (S) phases of captured RISC were incubated with 124-nt
32P-
cap-labeled GFP target mRNA. The reactions were stopped after 120 min,
and products were resolved on 6% denaturing polyacrylamide gels.
(C) Biotin-captured RISC contains proteins associated with mRNA
processing. Active human RISC from HeLa cells expressing Flag-Ago1
was captured by biotin-siRNA and its protein composition was analyzed
by immunoblot using anti-Flag, anti-Ago2, anti-RCK/p54, anti-Lsm1, and
anti-eIF4E antibodies.
DOI: 10.1371/journal.pbio.0040210.g002
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that occurred in P-bodies (Figure 1A) was RNA-dependent,
and eIF4E did not directly interact with Ago2 to assemble
into active RISC by the guide strand. The data also show that
Lsm1 was not a RISC component, consistent with ﬁndings
shown in Figure 1A. Together, these results identify a new
argonaute-interacting protein, RCK/p54, that is recruited to
siRISC.
RCK/p54 Is a Component of RISC Containing miRNA
To determine the functional interactions of RCK/p54 with
miRISC, we employed afﬁnity puriﬁcation of RISC and target
mRNA cleavage capabilities of miRISC when the target has
perfectly complementary sequences to the miRNAs. Cell
extracts containing let-7 miRISC cleaved perfectly matched
radiolabeled target mRNA with high efﬁciencies, whereas a
substrate mRNA containing a mismatched sequence was not
cleaved (Figure 3A, lanes 2 and 3). In the absence of extracts,
no mRNA cleavage or degradation was detected (Figure 3A,
lane 1). After establishing the functional assay to analyze
miRISC, we next afﬁnity-puriﬁed miRISC on magnetic beads
using anti-Ago2 and anti-RCK/p54 antibodies and assessed
the cleavage of perfectly matched let-7 target mRNA by the
bead and supernatant phases. miRISCs puriﬁed by anti-Ago2
and anti-RCK/p54 antibodies showed efﬁcient cleavage of let-
7 target mRNA (Figure 3A, lanes 7 and 9). Ago2 antibodies
captured most of the RISC activity on beads as compared to
RCK/p54 antibodies (Figure 3A, lanes 6–9). Non-speciﬁc IgG
did not purify miRISC activities on beads (Figure 3A, lanes 4
and 5). These results demonstrate that RCK/p54 is a
component of functional miRISC.
To conﬁrm these results, we next used an alternative
approach to determine whether RCK/p54 is associated with
endogenous RISC programmed by miRISC. RISCs containing
miRNA were isolated from HeLa cells by afﬁnity-capture as
described in Figure 2A, with the following modiﬁcations. To
speciﬁcally capture endogenous miRISC, 29-O-methyl (29-O
Me) inhibitors of let-7 miRNA were employed [54,55]. HeLa
cytoplasmic extracts expressing Myc-Ago1 and Flag-Ago2
were incubated with 39-biotinylated-let-7–29-O-Me inhibitor,
which is complementary to the let-7 miRNA, and incubated
with streptavidin-conjugated magnetic beads. As a control,
cell extracts were treated with the let-7–29-O-Me inhibitor
without 39-biotinylation. After capture, beads containing
miRISCs were washed with lysis buffer and split into two
aliquots to determine miRISC function and protein compo-
sition. Function was determined by assaying for in vitro
cleavage of a
32P-target mRNA that perfectly matched the let-
7 sequence. The data in Figure 3B (lanes 1 and 4) show that
cell extracts containing active let-7 miRISC cleaved the
perfectly matched target mRNA with high efﬁciencies
[54,55]. Incubation with let-7 inhibitors (with or without 39-
Figure 3. RCK/p54 Is a Component of Human miRISC
(A) Affinity-purified miRISCs associated with PCK/p54 retain cleavage activity. To purify miRISC associated with RCK/p54, magnetic protein A beads
coupled with rabbit IgG, rabbit anti-Ago2, or rabbit anti-RCK/p54 antibodies were incubated with HeLa cytoplasmic extracts. After
immunoprecipitation, RISC activities were analyzed by incubating the supernatant (S) or bead (B) phases with 182-nt
32P-cap-labeled let-7 substrate
mRNAs having a perfectly complementary or mismatched sequence to the let-7 miRNA. Cleavage products were resolved on 6% denaturing
polyacrylamide gels. CE, cytoplasmic extract; PM, perfect match; MM, mismatch.
(B) Affinity-purified miRISCs retain cleavage activity. let-7 miRISC cleavage of a perfectly matched RNA target was inhibited by 29-O-Me oligonucleotides
complementary to let-7 miRNA (let-7–29-O-Me or let-7–29-O-Me-biotin). A 182-nt 32P-cap-labeled let-7 substrate mRNA was incubated with the
supernatant (S) or bead (B) phases of captured miRISC. The reactions were stopped after 120 min, and products were resolved on 6% denaturing
polyacrylamide gels.
(C) miRISCs contain proteins associated with mRNA processing. Cytoplasmic extracts of HeLa cells expressing Flag-Ago2 and Myc-Ago1 were incubated
with 29-O-Me oligonucleotides complementary to let-7 miRNA (let-7–29-O-Me or let-7–29-O-Me-biotin), affinity-purified by streptavidin-magnetic beads
to capture let-7 miRISC. Supernatant (S) and beads (B) after biotin capture were analyzed by immunoblot using anti-Myc, anti-Flag, anti-RCK/p54, and
anti-eIF4E antibodies.
DOI: 10.1371/journal.pbio.0040210.g003
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supernatant or beads (Figure 3B, lanes 2–3, and lanes 5–6).
These results are consistent with previous reports [54,55] that
adding 29-O-Me oligonucleotides complementary to let-7
abolishes target cleavage activity by let-7 in cell extracts,
indicating complete hybridization of the 29-O-Me probe.
Immunoblot analysis of afﬁnity-puriﬁed miRISC using anti-
Myc, anti-Flag, anti-RCK/p54, and anti-eIF4E antibodies
(Figure 3C) showed that Myc-Ago1, Flag-Ago2, and RCK/p54
were associated with let-7 miRISC. As observed for the active
RISC programmed with siRNA, eIF4E did not associate with
miRISC. These ﬁndings reveal that RCK/p54 is a novel
component of endogenous RISC programmed with either
siRNA or miRNA.
Depletion of RCK/p54 Disrupts P-Bodies and Ago2
Localization
To understand the function and role of RCK/p54 in the
RNAi pathway, RCK/p54 was depleted in P-bodies of HeLa
cells by siRNA-mediated RNAi. 24 h after transfecting cells
with siRNA, real-time quantitative PCR showed that mRNA
levels decreased by more than 90% and immunoblot analysis
showed that RCK/p54 protein levels decreased signiﬁcantly
without affecting the levels of other P-body proteins
including Lsm1 and Ago2 (Figure S2). The effect of depleting
RCK/p54 on localization of Ago2 was next examined by
immunoﬂuorescence analysis of HeLa cells expressing Myc-
Ago2 and siRNAs against RCK/p54. As shown in Figure 4B,
4C, 4F, and 4G, depleting RCK/p54 disrupted the cellular P-
body structures. In these P-body-deﬁcient cells, Ago2 proteins
were diffused throughout the cytoplasm and no longer
accumulated at speciﬁc foci (Figure 4A and 4E). This
cytoplasmic redistribution of Ago2 suggests that its local-
ization to P-bodies is driven in mammalian cells by factors
such as RCK/p54.
Depletion of Lsm1 Disrupts P-Bodies but Does Not Affect
RCK/p54 and Ago2 Interactions
The interactions between the P-body proteins, RCK/p54,
and argonautes raised the question whether P-body struc-
tures are required for these interactions. To address this
question, we disrupted P-body structures by using RNAi
against Lsm1, which is a P-body protein that does not
associate with RISC as shown in Figure 1. HeLa cells were
transfected with siRNA against Lsm1, harvested at 24, 48, and
72 h post-transfection, and TCEs were analyzed by immuno-
blot. The results show an efﬁcient knockdown of Lsm1
without changing the levels of RCK/p54, Ago2, and GAPDH
(Figure 5A). We next visualized Lsm1 and Ago2 by immuno-
ﬂuorescence using antibodies against Lsm1 and Myc tag and
found that Lsm1 and Ago2 co-localized in P-bodies (Figure
5B). To determine the status of P-body structures and RISC
localization in cells after Lsm1 knockdown, Lsm1-depleted
cells were analyzed by immunoﬂuorescence. We found that P-
body structures were drastically disrupted, Ago2 was diffused
throughout the cytoplasm, and Lsm1 and Ago2 were
minimally co-localized (Figure 5B). These results show that
P-body structures were drastically disrupted and Ago2 was
diffuse throughout the cytoplasm when Lsm1 was depleted by
RNAi.
To determine the effect of P-body disruption on Ago2 and
RCK/p54 interactions, we immunopuriﬁed Myc-Ago2 and
RCK/p54 after Lsm1 knockdown. HeLa cells were transfected
for 48 h with Myc-Ago2 and control siRNA or siRNA against
Lsm1, TCEs were prepared, and Myc-Ago2 was immunopre-
cipitated from an aliquot of TCE. TCEs and anti-Myc
immunoprecipitation products were analyzed by immunoblot
using anti-Myc, anti-RCK/p54, and anti-Lsm1 antibodies.
Lsm1 siRNA treatment efﬁciently depleted Lsm1 protein
levels without affecting Myc-Ago2 and RCK/p54 levels (Figure
5C). Immunoprecipitation using Myc antibodies showed that
RCK/p54 interacted with Ago2 and this interaction was not
signiﬁcantly changed by depleting Lsm1 (Figure 5C). Since P-
bodies were disrupted by Lsm1 depletion, these results
demonstrate that Ago2 and RCK/p54 interaction does not
require P-bodies.
Next, we analyzed the target mRNA cleavage activities of
afﬁnity-puriﬁed miRISC from Lsm1-depleted cell extracts. P-
bodies were disrupted in HeLa cells by transfecting them with
Figure 4. Depletion of RCK/p54 Disrupts P-bodies and Disperses the Localization of Human Ago2
HeLa cells were co-transfected with Myc-Ago2 and siRNA against human RCK/p54 (lower panels) or CDK9 mismatch (control; upper panels). At 24 h
post-transfection, cells were analyzed by immunofluorescence using antibodies against Myc-Ago2 (A and E) and against the P-body proteins Lsm1 (B
and F) and RCK/p54 (C and G). Cells were stained with Hoechst 33258 to visualize nuclei and images were digitally merged (D and H).
DOI: 10.1371/journal.pbio.0040210.g004
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48 h post-transfection. These HeLa cell extracts were
incubated with magnetic protein A beads coupled with rabbit
IgG, rabbit anti-Ago2, or rabbit anti-RCK/p54 antibodies to
purify miRISC associated with RCK/p54 or Ago2. After
immunoprecipitation, RISC activities were analyzed by
incubating the supernatant (S) or bead (B) phases with 182-
nt
32P-cap-labeled let-7 substrate mRNAs having a perfectly
complementary or mismatched sequence to the let-7 miRNA.
Cleavage products were resolved on 6% denaturing poly-
Figure 5. Depletion of Lsm1 Disrupts P-Bodies but Does Not Affect the Interaction between RCK/p54 and Ago2
(A) Specific knockdown of Lsm1 in HeLa cells by siRNA. HeLa cells were transfected with siRNA against Lsm1 and harvested at 24, 48, and 72 h post-
transfection, and TCEs were analyzed by immunoblot with antibodies against Lsm1 or GAPDH.
(B) Depletion of Lsm1 disrupts P-bodies. HeLa cells were transfected with siRNA against Lsm1. At 48 h post-transfection, cells were analyzed by
immunofluorescence using antibodies against Lsm1 and Myc tag for Ago2. Cells were stained with Hoechst33258 to visualize nuclei, and images were
digitally merged.
(C) RCK/p54 interacts with Myc-Ago2 in Lsm1-depleted cells. HeLa cells were transfected for 48 h with Myc-Ago2 and control siRNA or siRNA against
Lsm1, TCEs were prepared, and Myc-Ago2 was immunoprecipitated from an aliquot of TCE. TCE and anti-Myc IPs were analyzed by immunoblot using
anti-Myc, anti-RCK/p54, and anti-Lsm1 antibodies.
(D) Affinity-purified RCK/p54 and Ago2 from Lsm1-depleted cell extracts retain miRISC activity. HeLa cells were transfected for 48 h with siRNA against
Lsm1, and cytoplasmic extracts were prepared. These extracts were incubated with magnetic protein A beads coupled with rabbit IgG, rabbit anti-Ago2,
or rabbit anti-RCK/p54 antibodies to purify miRISC associated with RCK/p54. After immunoprecipitation, RISC activities were analyzed by incubating the
supernatant (S) or bead (B) phases with 182-nt
32P-cap-labeled let-7 substrate mRNAs having a perfectly matched or a mismatched sequence to the let-7
miRNA. Cleavage products were resolved on 6% denaturing polyacrylamide gels. MM, mismatch.
DOI: 10.1371/journal.pbio.0040210.g005
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Translational Repression by Human RISCacrylamide gels. miRISCs puriﬁed by anti-Ago2 and anti-
RCK/p54 antibodies showed efﬁcient target let-7 cleavage
(Figure 5D, lanes 4 and 6). Ago2 antibodies captured more
RISC activity on beads than RCK/p54 antibodies, as also
observed in Figure 3A (lanes 6–9). Control experiments using
IgG (Figure 5D, lanes 1 and 2) did not show any miRISC
activity puriﬁed by magnetic beads, supporting speciﬁc
capture by Ago2 and RCK/p54 antibodies (Figure 5D, lanes
4 and 6). miRISC did not cleave a mismatched substrate RNA
for let-7 (Figure 5D, lane 7). Despite the signiﬁcant loss of P-
body structures in cells treated with Lsm1 siRNA, the
efﬁciency of let-7 target mRNA cleavage by miRISC puriﬁed
by anti-RCK/p54 antibody was not signiﬁcantly affected
(compare Figure 3A, lane 9 with Figure 5D, lane 6). These
results indicate that disrupting P-bodies by depleting Lsm1
did not signiﬁcantly affect RCK/p54 association with miRISC.
Depletion of RCK/p54 Does Not Affect RNAi Activity In
Vivo
To examine whether the P-body protein RCK/p54, also a
component of RISC, is involved in siRNA-mediated gene
silencing, the siRNA dose dependence of RNAi-mediated
gene silencing was quantiﬁed in RCK/p54-depleted HeLa cells
using a dual ﬂuorescence reporter assay. Brieﬂy, GFP and red
ﬂuorescent protein (RFP) were constitutively expressed in
cells transfected with reporter plasmids for enhanced GFP
(EGFP) and RFP, respectively. GFP expression was silenced by
treating cells with a 21-nt siRNA targeting nt 238–258 of the
EGFP mRNA. The ﬂuorescence intensity ratio of target (GFP)
to control (RFP) ﬂuorophore was determined in the presence
of siRNA duplexes and normalized to that observed in
control-treated cells [52].
When HeLa cells were transfected with siRNA mismatched
for CDK9 (control), the second transfection with GFP siRNA
silenced GFP expression in a dose-dependent manner, i.e.,
GFP/RFP ratios decreased with increasing concentrations of
siRNA (Figure 6A, gray bars). Depleting RCK/p54 before
quantifying GFP silencing resulted in moderate to no
signiﬁcant loss of RNAi activity, i.e., GFP/RFP again decreased
with increasing concentrations of siRNA (Figure 6A, green
bars). Similarly, depleting Lsm1 (Figure 6A, red bars) and the
decapping enzyme, Dcp2 (unpublished data), before quanti-
fying GFP silencing in HeLa cells did not signiﬁcantly
decrease RNAi activity. In contrast, prior depletion of Ago2
completely abolished RNAi activity (Figure 6A, blue bars), as
expected and consistent with previous reports [14–16]. These
results suggest that depleting RCK/p54, which disrupts P-
bodies (Figure 4), did not signiﬁcantly affect siRNA-mediated
RNAi in vivo.
Depletion of RCK/p54 Does Not Affect RISC-Mediated
mRNA Cleavage In Vitro
To examine the role of RCK/p54 in RISC catalysis of mRNA
processing, in vitro mRNA cleavage activity was assayed in
extracts from RCK/p54-depleted HeLa cells. Cells were
transfected with siRNAs against CDK9 mismatch (control),
RCK/p54, Lsm1, or Ago2 and programmed 24 h later with
GFP siRNA. Varying amounts of cytoplasmic extract (20–100
lg) were assayed in vitro for target mRNA cleavage activity.
As shown in Figure 6B and 6C, cleavage activity increased
with increasing protein concentration of extracts from both
control and RCK/p54-depleted cells, reaching a robust
cleavage (37%–41%) of target mRNA at the highest protein
concentration (100 lg). In consistent with in vivo results
shown in Figure 6A, Ago2 depletion abolished the target
mRNA cleavage activities of RISC. These results show that
RCK/p54 does not affect the slicer function of RISC in
cleaving target mRNA in vitro.
Figure 6. Depletion of RCK/p54 Has No Significant Effect on RNAi
Activity In Vivo and In Vitro
(A) In vivo effect of depleting RCK/p54, Lsm1, and Ago2 on siRNA dose-
dependent RNAi activity. HeLa cells were transfected with siRNAs against
CDK9 mismatch (control), RCK/p54, Lsm1, or Ago2. 24 h later cells were
transfected again with EGFP and RFP reporter plasmids and varying
amounts (2, 10, and 50 nM) of siRNA against EGFP. 24 h after the second
transfection, RNAi efficiencies were analyzed (see Materials and
Methods). To quantify the effect of depleting RCK/p54 and Ago2 on
RNAi, the ratio of GFP/RFP signals was normalized to that observed in the
absence of GFP siRNA (0 nM). Normalized ratios , 1.0 indicate specific
RNAi at a given siRNA concentration.
(B) Depletion of RCK/p54 has no effect on in vitro siRISC cleavage activity.
HeLa cells were transfected with siRNAs targeting RCK/p54, Lsm1, Ago2,
or CDK9 mismatch (control). 24 h after the first transfection, cells were
again transfected with 50 nM siRNA targeting EGFP. 24 h later
cytoplasmic extracts were made (see Materials and Methods), and
varying amounts (20, 50, 100 lg) of total cytoplasmic extract protein
were incubated with a 124-nt, 32P-cap-labeled GFP target mRNA. The
reactions were stopped after 60 min, and products were resolved on 6%
denaturing polyacrylamide gels.
(C) Quantification of siRISC cleavage activity in vitro after depletion of
RCK/p54, Lsm1, or Ago2. Cleavage activity of siRISC targeting EGFP
mRNA was quantified as a function of protein content in extracts of HeLa
cells depleted of RCK/p54, Lsm1, or Ago2.
DOI: 10.1371/journal.pbio.0040210.g006
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Translation
Our results thus far demonstrate that RCK/p54 is a
component of human RISC (Figures 2 and 3) and enhances
P-body formation (Figure 1). Our data also show that siRNA-
mediated RNAi may not require RCK/p54 and P-body
cytoplasmic structures. Since we also identiﬁed that RCK/
p54 associates with miRISC, we hypothesized that RCK/p54
might function in miRNA-mediated suppression of trans-
lation. A recent and intriguing report [45] identiﬁed a yeast
homolog of RCK/p54, Dhh1p, which activates decapping and
facilitates P-body formation, as a general translation repress-
or. We therefore reasoned that RCK/p54 might be a general
translation repressor used by the miRNA machinery to
dictate translation suppression of target mRNAs. To test this
hypothesis, we ﬁrst determined whether RCK/p54 was a
general translation repressor in human cells. To this end,
RCK/p54 expression was silenced in HeLa cells and general
translational activity was analyzed by [
35S]methionine incor-
poration (Figure 7A). The translational rates measured by
[
35S]-labeling were signiﬁcantly greater in RCK/p54-depleted
cells than in control siRNA-treated cells (Figure 7A),
indicating that RCK/p54 was a translational repressor in
human cells, consistent with results in yeast and reticulocyte
extracts [45].
Since RCK/p54 is a general translational repressor and a
component of human RISC, we examined the effects of
depleting RCK/p54 and disrupting P-bodies on siRNA- and
miRNA-mediated gene silencing. To analyze siRNA- or
miRNA-mediated gene-silencing events, we chose a well-
established CXCR4 mRNA reporter system [56], in which
siRNA- or miRNA-reporter constructs harbor 1 3 perfectly
matched or 4 3 bulged CXCR4 siRNA target sites, respec-
tively, in the 39 UTR of Renilla reniformis luciferase (RL) mRNA
[56]. In this system, perfectly matched sequences are cleaved
by siRISC and bulge-containing sequences are targets for
translation suppression by miRISC. HeLa cells were co-
transfected with siRNAs directed against P-body proteins
(RCK/p54, GW182, Lsm1, and Ago2) and with siRNA or
miRNA reporters in the absence or presence of 25 nM
CXCR4 siRNA. At 24 h post-transfection, cells were harvested
and RL activities were analyzed. RL signals were normalized
to Photinus pyralis luciferase (FL) signals from cells co-
transfected with pGL3 plasmid as control. Depletion of
RCK/p54 released only miRNA-mediated gene suppression
and had no effect on siRNA-mediated gene silencing (Figure
7B). Depletion of GW182, an argonaute-interacting P-body
protein, released gene suppression by miRNA, consistent with
previous ﬁndings [39–41], and moderately released siRNA-
mediated gene silencing [40,41]. Ago2 depletion signiﬁcantly
released siRNA-mediated gene silencing and moderately
released miRNA-mediated gene suppression. Knockdown of
Lsm1 had no signiﬁcant effect on either miRNA- or siRNA-
mediated gene silencing. Taken together, these results show
that RCK/p54 depletion releases miRNA-mediated translation
suppression of reporter genes, but does not affect siRNA-
mediated RNAi.
We next hypothesized that the expression of a speciﬁc
cellular protein, known to be controlled by miRNAs, might be
up-regulated in RCK/p54-depleted cells. Such a protein,
human RAS, has been elegantly shown by Slack and
colleagues [13] to be regulated by the let-7 miRNA family.
To test our hypothesis, we analyzed RAS protein levels in
HeLa cells under two conditions: either let-7 function was
inhibited by 29-O-Me oligonucleotides complementary to the
let-7 sequence or RCK/p54 was depleted by RNAi (Figure 7C).
For control experiments, we treated cells with a CDK9 mm
siRNA and a 29 -O-Me oligonucleotide complementary to
HIV-1 TAR RNA sequence [53]. Total cellular protein
extracts from equal numbers of cells were prepared and
analyzed by immunoblot using monoclonal anti-RAS anti-
bodies directly conjugated with HRP (see Materials and
Methods). Actin protein levels were measured as a control
using HRP-conjugated anti-actin primary antibody. When
cells were treated with let-7 inhibitor, RAS protein levels
increased, consistent with previous ﬁndings [13]. Strikingly,
RAS protein expression in RCK/p54-depleted cells also
showed a robust increase (Figure 7C) while RAS levels were
not signiﬁcantly affected when cells were treated with control
siRNA or 29-O-Me oligonucleotides. RAS mRNA levels did not
differ drastically in HeLa cells after treatment with let-7
inhibitor, RCK/p54 silencing, or mock treatment (Figure S3).
To further probe our ﬁndings of endogenous RAS
regulation by RCK/p54, we co-transfected HeLa cells with
RAS 39 UTR reporter constructs and let-7 29 -O-Me inhibitor
or siRNA against RCK/p54. For control experiments, we
treated cells with a CDK9 mm siRNA and a 29 -O-Me
oligonucleotide complementary to HIV-1 TAR RNA sequence
[53]. Cells transfected with a control siRNA and let-7 inhibitor
induced more ﬁreﬂy luciferase expression when reporter
plasmids contained 39 UTR sequences for NRAS and KRAS
than for the control siRNA and a 29-O-Me oligo control
(Figure 7D), consistent with a recent report [13]. Depleting
RCK/p54 by siRNA and adding a control 29-O-Me oligo also
released translation repression from both NRAS and KRAS
vectors. Interestingly, combining these two approaches to
release translation suppression, let-72 9-O-Me oligo and RCK/
p54 depletion, did not show additive effects to induce NRAS
and KRAs expression. In all of these experiments, slightly
greater ﬁreﬂy luciferase expression was induced from pGL3-
NRAS than from KRAS vectors. These results, combined with
those of Figure 7A–C, strongly suggest that RCK/p54 is a
general translation repressor that associates with RISC to
regulate miRNA-mediated translation repression.
Discussion
We have identiﬁed RCK/p54 as a protein that interacts with
Ago2 in afﬁnity-puriﬁed RISC assemblies to facilitate
formation of cytoplasmic P-bodies and that acts as a general
translational repressor in human cells. We have shown that
depletion of RCK/p54 disrupts P-bodies and disperses the
cytoplasmic localization of Ago2. Furthermore, depletion of
RCK/p54 did not signiﬁcantly affect the RNAi function of
RISC, although general, miRNA-mediated, and let-7-mediated
translational repression were released. Together, our results
provide signiﬁcant insights into miRNA mechanisms in
human cells (see below).
Several recent reports show that RISC co-localizes with P-
bodies, suggesting that they could be the site where RISC
degrades target mRNA or represses mRNA translation [28–
31]. Isolation of miRNAs on polysomes also links the
suppression of protein synthesis with arrest of translation
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that human Ago1 and Ago2 co-localize in P-bodies with other
cellular proteins, such as Dcp1a, Dcp2, GW182, Lsm1, and
Xrn1 [28–31]. A homolog of the P-body protein GW182 in
Caenorhabditis elegans is the developmental timing regulator
AIN-1, which also interacts with miRISCs and may target
argonaute proteins to P-bodies [57]. To dissect and under-
stand the relationship between RNAi function and P-bodies,
we afﬁnity-puriﬁed RISC using Myc-Ago2 and expression
vectors of the YFP-tagged P-body proteins, Lsm1, RCK/p54,
Dcp2, and eIF4E. Ago2 interacted with these various P-body
components in ways that were RNA-dependent or RNA-
independent (Figure 1A). Ago1 and RCK/p54 immunopreci-
pitated with Ago2 after RNase A treatment of HeLa cell
extracts, suggesting that these proteins directly interact with
Ago2. Interestingly, RCK/p54, Ago1, and Ago2 were also
identiﬁed as a component of active RISC programmed with
siRNA or miRNA and puriﬁed by biotin afﬁnity to strepta-
vidin-conjugated magnetic beads (Figures 2 and 3). We
examined the P-body localization of Ago2 with Lsm1 and
Figure 7. RCK/p54 Represses General and miRNA-Mediated Translation
(A) Release of general translational repression by silencing RCK/p54. Incorporation of [
35S]methionine into HeLa cells was used to measure general
translational activity. Cells were transfected with 50 nM siRNAs targeting mismatched CDK9 (control) or RCK/p54. Mock control cells were treated with
the transfection reagent only. At 24 h post-transfection, cells were incubated for 1 h in medium lacking Met and Cys, and metabolically labeled with
[
35S]methionine (see Materials and Methods). As a control for passive uptake of [
35S], mock cells were treated with 40 lg/ml of the translation inhibitor,
cycloheximide. Cell incorporation of [
35S] is shown as cpm/10
6 cells versus time after adding [
35S].
(B) Depletion of RCK/p54 releases translational repression in a luciferase reporter system. HeLa cells were transfected with siRNAs against CDK9 mm
(control), RCK/p54, GW182, Lsm1, or Ago2. 24 h later, cells were co-transfected with siRNA (13perfectly matched [PM] site) or miRNA (43bulged sites)
luciferase reporters in the presence of CXCR4 siRNA. RL activities were measured 24 h after the second transfection and normalized to FL activity as a
control. Repression of reporter gene expression by siRNA or miRNA were measured by normalizing the RL/FL signals in the presence of CXCR4 siRNA to
the RL/FL activities observed in the absence of siRNA. Release of gene repression by siRNA or miRNA is presented as the fold induction of RL/FL
activities compared to the RL/FL signals observed in control (si-CDK9mm) experiments. FL, firefly luciferase.
(C) Depletion of RCK/p54 releases repression of RAS protein translation. HeLa cells were transfected with 100 nM of 29-O-Me oligonucleotide (let-7 29-O-
Me inhibitor or 29-O-Me control), and siRNA against RCK/p54 or CDK9 mm control. 24 h after transfection, the cells were counted and harvested (see
Materials and Methods). The protein contents of TCEs were resolved by SDS-PAGE and analyzed by immunoblot using anti-RAS and anti-actin
antibodies.
(D) Depletion of RCK/p54 releases repression of luciferase protein translation by 39 UTRs of NRAS and KRAS. HeLa cells transfected with an Rr-luc-
expressing vector, pRL-TK, and a Pp- luc-expressing vector, pGL3-control, pGL3-NRAS, or pGL3-KRAS, were co-transfected with 100 nM of 29-O-Me
oligonucleotide (let-7 29-O-Me inhibitor or 29-O-Me control) and siRNA against RCK/p54 or CDK9 mm control. TCEs were prepared 48 h post-transfection
and dual luciferase assays were performed. Relative GL (Pp-luc)/RL (Rr-luc) signals were normalized to those of pGL3-control-transfected cells and are
shown as the fold induction compared to mock treatment.
DOI: 10.1371/journal.pbio.0040210.g007
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with CFP-Ago2. Interestingly, overexpressing YFP-RCK/p54
in HeLa cells increased the number of P-bodies (from ; 8t o
; 20 foci/cell). The number of P-bodies containing CFP-Ago2
also increased (Figure 1B). These results suggested a func-
tional relationship between RCK/p54-Ago interactions and
their localization to P-bodies. To visualize protein–protein
interactions in vivo, we used FRET as a probe. In cells
expressing YFP-RCK/p54 and CFP-Ago2, the FRET efﬁciency
was 21.07% 6 2.52% (Figure 1C and 1D). We also observed an
efﬁcient FRET between YFP-Ago1 and CFP-Ago2; however,
FRET between RCK/p54 and Ago1 was moderate (6.41% 6
1.96%). Since FRET is quite sensitive to the orientation of the
donor: acceptor pair, it is possible that CFP and YFP in Ago1
and RCK/p54 are not suitably positioned for efﬁcient energy
transfer. Nonetheless, the FRET efﬁciency between Ago1 and
RCK/p54 was signiﬁcantly above the 0.9% background. Taken
together, these results demonstrate that Ago1, Ago2, and
RCK/p54 directly interact in vivo.
Where in the cell does this physical interaction between
RISC and RCK/p54 take place and does it require P-body
structures? To address these questions, we disrupted P-bodies
in cells by depleting Lsm1 and immunopuriﬁed endogenous
miRISC, and analyzed its ability to cleave a target mRNA with
perfect complementarity to let-7 miRNA (Figure 5). We
observed no signiﬁcant difference in miRISC activities
puriﬁed from Lsm1-depleted and non-depleted cells (Figures
3 and 5) even though the P-body structures were disrupted
and the total number of P-bodies per cell had signiﬁcantly
decreased. These results show that RCK/p54 association with
RISC does not require P-bodies and suggest that localization
of RISC to P-bodies is the outcome of translation repression
by miRISC.
Having established the physical interactions of RCK/p54
with RISC, we questioned the functional relevance of these
interactions in the RNAi pathway and how they could
facilitate RISC activity. To that end, we depleted RCK/p54
in HeLa cells and analyzed RNAi activities in vivo and in vitro
(Figure 6). Depletion of RCK/p54 clearly disrupted the P-body
structures and dispersed Ago2 localization throughout the
cytoplasm (Figure 4). Surprisingly, depleting RCK/p54 did not
signiﬁcantly affect siRNA-mediated gene silencing. Similar
results showing the lack of P-body involvement in RNAi have
been reported in Drosophila [39]. In that system, depletion of
the P-body proteins, GW182 or Dcp1:Dcp2 decapping
complex, showed that these proteins were required for
miRNA-mediated gene silencing, but RNAi efﬁciency was
not affected, suggesting that these two gene-silencing
mechanisms were independent in Drosophila [39]. In addition,
two recent studies reported that mammalian GW182 interacts
with Ago2 and plays a role in miRNA function [40] and in
siRNA-mediated RNAi [41]. Interestingly, depleting GW182
disrupted cytoplasmic foci and interfered with RNAi activity
[41]. It is possible that GW182 is directly involved in human
RISC function and does not spatially require P-bodies for its
function. As an alternative approach to disrupting P-bodies,
we treated HeLa cells with the translation inhibitor, cyclo-
heximide, which did not signiﬁcantly affect RNAi activities in
vivo and in vitro (unpublished data). Taken together, these
results strongly suggest that functional siRISC is assembled
before locating to P-bodies, and P-bodies are not prerequisite
sites for siRNA-mediated gene silencing.
To determine the role of RCK/p54 in miRNA-mediated
translation repression, we used a CXCR4 reporter system [56],
in which siRNA- or miRNA-reporter constructs harbor 1 3
perfectly matched or 4 3 bulged CXCR4 siRNA target sites,
respectively in the 39 UTR of RL mRNA [56]. In this system,
perfectly matched sequences are cleaved via siRISC and
bulge-containing sequences are targets for translation sup-
pression by miRISC. We observed that depletion of RCK/p54
released only miRNA-mediated gene suppression and had no
effect on siRNA-mediated gene silencing (Figure 7B). Deple-
tion of GW182, an argonaute-interacting P-body protein,
released gene suppression by miRNA and moderately affected
reporter constructs containing perfectly matched target
sequences, consistent with previous ﬁndings [39–41]. Ago2
depletion signiﬁcantly released siRNA-mediated gene silenc-
ing and moderately affected reporters containing 4 3 bulged
sequences. Knockdown of Lsm1 had no signiﬁcant effect on
either miRNA- or siRNA-mediated gene silencing. These
results show that RCK/p54 depletion releases miRNA-medi-
ated translation suppression of reporter genes and that this
function of RCK/p54 was not signiﬁcantly affected when P-
bodies were disrupted by depleting Lsm1.
To test our hypothesis that RCK/p54 mediates the trans-
lational repression of endogenous miRNA targets in P-bodies,
we examined RAS protein levels in RCK/p54-depleted cells.
We chose RAS because it is an endogenous target of let-7, and
39 UTRs of human RAS genes contain multiple complemen-
tary sites for let-7 to bind and regulate RAS expression levels
[13]. Furthermore, let-7 inhibitors are known to enhance RAS
protein expression in HeLa cells [13]. Depleting RCK/p54 in
HeLa cells up-regulated RAS protein, and this increase in
RAS levels was higher than that in general translation of
control actin (Figure 7C), suggesting that multiple sites of let-
7 miRISC binding to target 39 UTR dictate the potency and
speciﬁcity of translation suppression.
RCK/p54, the human homolog of yeast Dhh1p, is a member
of the ATP-dependent DEAD box helicase family and was
originally identiﬁed as a proto-oncogene [42]. In human cells,
RCK/p54 interacts in P-bodies with the translation initiation
factor, eIF4E [33]. The Xenopus homolog of RCK/p54, Xp54,
which interacts with eIF4E and forms RNA-dependent
oligomers, represses the translation of mRNA in oocytes
and eggs [43]. In yeast, Dhh1p interacts with the decapping
and deadenylase complex and functions in translational
repression [44]. Dhh1p has recently been shown to stimulate
translational repression by inhibiting production of the pre-
initiation complex [45]. Dhh1p and RCK/p54 also inhibit the
mRNA translation driven by internal ribosomal entry sites in
vitro, suggesting that this protein is a general translational
repressor that may not require a cap structure for its function
[45]. However, the in vivo function of Dhh1p required
translational initiation [45]. Translation repression by miR-
ISC and P-body localization require the 59-cap structure in
the target mRNA [29,58], which provides a unique and elegant
control mechanism for translation and its regulation (re-
viewed in [59,60]). Recently, Petersen et al. reported an
intriguing study showing that miRNA represses translation
after initiation by a ribosome drop-off mechanism [61].
Therefore, it is possible that RCK/p54 interacts with miRISC
and blocks translation elongation by binding to its multiple
target sites with high afﬁnity and creates a barrier for
elongating ribosomes (see below).
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in cells can be described by a model with two independent
pathways, depending on whether RNAi is programmed by the
guide strand of siRNA or miRNA. In the ﬁrst pathway, the
RISC recognizes a perfectly matched target mRNA and
functions as siRISC (Figure 8) by cleaving its target mRNA.
This target mRNA cleavage activity and rapid turnover of
siRISC induce the subsequent target mRNA degradation by
exonucleases and does not require P-bodies. In the second
pathway, the RISC recognizes the imperfectly matched target
and functions as miRISC (Figure 8). Multiple copies of
miRISC containing RCK/p54 could initiate an oligomeriza-
tion event that sequesters the whole RNP and transports it to
the P-bodies. This sequestration could also explain the
cooperative effects of RISC function that enhance translation
repression [56]. Once in P-bodies, translationally repressed
mRNA could stay in oligomeric structures for storage or it
could form a complex with decapping enzymes and cap
binding proteins that would lead to the mRNA decay
pathway. In other words, the miRNA in RISC could provide
the sequence speciﬁcity and RCK/p54 could be the effector
molecule that shuttles the target mRNA toward the fate of
storage or processing in P-bodies. Since P-bodies are not a
prerequisite for RCK/p54 to assemble into RISC or to
function, it is possible that miRISC blocks protein synthesis
by enhancing the ribosome drop-off during elongation of
translation [61]. We propose that miRISC localization to P-
bodies is the outcome of translation repression and not a
prerequisite for miRISC function. Stored mRNA in P-bodies
could reenter the active translation or mRNA decay pathway
depending upon cellular conditions or stimuli that are
presently unknown. How long mRNA translation can be
repressed in the cytoplasm and which factors trigger mRNA
transport to P-bodies are exciting areas for future research.
Our results on the interactions between RCK/p54 and the
RNAi machinery suggest an intriguing role for miRNA
function in development and carcinogenesis. However, most
targets of miRNA have not yet been identiﬁed. A growing
body of evidence suggests that miRNAs are important in
human disease, including cancers [9–12]. For example,
relatively low levels of let-7 miRNA up-regulate RAS protein
in lung cancer cells, demonstrating a possible role of miRNA
in tumorigenesis [13]. Two homologs of RCK/p54, Xp54 in
Xenopus and Me31b in Drosophila, control the translation of
maternal mRNA in oocytes [43,62,63]. Altered regulation of
RCK/p54 expression levels has been implicated in the
development of human colorectal tumors [64,65] and in
hepatitis C virus-related chronic hepatitis [66]. Overexpres-
sion of RCK/p54 and Dhh1p increases the number of Ago2-
containing P-bodies (Figure 1B; [33,45]), suggesting that RCK/
p54 is a critical factor in controlling cellular translation. Our
results have identiﬁed RCK/p54 as an essential component of
miRISC-mediated translation repression and provide a func-
tional link between miRISC and P-bodies. In the context of
spatially and temporally restricted miRNA expression, this
system allows for exquisite regulation of protein expression
by target mRNA. Therefore, perturbations of either miRNA
or RCK/p54 expression levels can have deleterious conse-
quences for the cell. What determines the balance between
active translation and repression of mRNAs targeted by
Figure 8. A Model for Human RISC Function Involving miRNA and siRNA
RISC contains Ago2 (red), Ago1 (green), RCK/p54 (blue, labeled p54), and other known (e.g., Dicer and TRBP) and unidentified proteins (pink) and is
distributed throughout the cytoplasm. siRISC binds to its target mRNA by perfectly matching base pairs, cleaves the target mRNA for degradation,
recycles the complex, and does not require P-body structures for its function. Multiple numbers (n) of miRISC bind to target mRNA by forming a bulge
sequence in the middle that is not suitable for RNA cleavage, accumulate in P-bodies, and repress translation by exploiting global translational
suppressors such as RCK/p54. The translationally repressed mRNA is either stored in P-bodies or enters the mRNA decay pathway for destruction.
Depending upon cellular conditions and stimuli, stored mRNA can either re-enter the translation or mRNA decay pathways.
DOI: 10.1371/journal.pbio.0040210.g008
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Materials and Methods
Expression vectors. Ago1 and Ago2 expression vectors with N-
terminal YFP- or CFP-epitope tags were generated by PCR
ampliﬁcation of Ago1 and Ago2 coding sequences from pMyc-Ago1
and pMyc-Ago2 followed by cloning into the XbaI and EcoRI sites of
pEYFP-C1 and pECFP-C1 (BD Biosciences, Palo Alto, California,
United States). Expression vectors were kindly provided by four
laboratories: pMyc-Ago1/2 (Dr. G. Hannon); pFlag-Ago1/Ago2 (Dr. T.
Tuschl); pGL3-control, pGL3-KRAS, and pGL3-NRAS (Dr. F. Slack);
and pRL-TK-1P and pRL-TK-4B (Dr. P. Sharp).
Vectors for expressing YFP-tagged Lsm1, RCK/p54, eIF4E, and
Dcp2 were generated through PCR ampliﬁcation of their coding
sequences from 293T cDNA followed by cloning into the BglII and
SalI sites of pEYFP-C1 [67].
siRNAs. siRNAs against GFP, human Ago2, RCK/p54, Lsm1, and
CDK9 mismatch were synthesized by Dharmacon (Dharmacon,
Lafayette, Colorado, United States) and 29-OH deprotected according
to the manufacturer’s protocols. The sequences of siRNAs (passenger
strand) for our experiments were:
GFP: 59-GCAGCACGACUUCUUCAAGdTdT-39;h A g o 2 :5 9-
GCACGGAAGUCCAUCUGAAdTdT-39
RCK/p54: 59-GCAGAAACCCUAUGAGAUUUU-39; CDK9mm: 59-
CCAAAGCUCUCCCCUAUAAdTdT-39;L s m 1 :5 9-GUGACAUC-
CUGCCACCUCACUU-39
Cell culture and transfection. HeLa cells were cultured in
Dulbecco’s minimal essential medium (DMEM) with 10% fetal bovine
serum (FBS) at 37 8C with 5% CO2. Cells were transfected using
Lipofectamine (Invitrogen, Carlsbad, California, United States)
according to the manufacturer’s protocol.
Immunoprecipitation and immunoblotting. TCEs were prepared
by incubating cells in lysis buffer (20 mM HEPES [pH 7.9], 10 mM
NaCl, 1 mM MgCl2, 0.2 mM EDTA, 0.35% [v/v] Triton X-100, 1/100 [v/
v] dilution in protease inhibitor cocktail) and centrifuging at 14,000
rpm for 10 min at 4 8C. Protein concentration was determined by Dc
protein assay (Bio-Rad, Hercules, California, United States). To
examine the RNA dependence of protein–protein interactions, TCEs
(250 lg) were treated before immunoprecipitation with 0.2 lg/ul of
RNase A for 20 min at room temperature. Myc-tagged proteins were
precipitated by incubating overnight with polyclonal rabbit anti-Myc
antibodies directly conjugated to agarose beads (Santa Cruz Biotech,
California, United States). Samples were washed four times in lysis
buffer and eluted by boiling for 5 min at 100 8C in SDS-PAGE sample
loading buffer, separated by SDS-PAGE, and analyzed by immuno-
blot. For immunoblotting, antibodies included monoclonal mouse
anti-GFP (BD Biosciences), anti-eIF4E and anti-Myc (Santa Cruz
Biotech), anti-Flag (Sigma, St. Louis, Missouri, United States);
polyclonal rabbit anti-Myc (Santa Cruz Biotech), anti-DDX6 (rck/
p54; Bethyl Laboratories, Montgomery, Texas, United States); and
polyclonal chicken anti-Lsm1 (GenWay Biotech Incorporated, San
Diego, California, United States).
To assess the ability of endogenous immunopuriﬁed miRISC to
cleave target mRNA with perfect complementarity to let-7 miRNA, in
vitro cleavage assays for let-7 miRISC were conducted. Aliquots (30 ll)
of magnetic protein A beads (Dynal, Norway) were preincubated with
rabbit IgG, anti-Ago2, or anti-RCK/p54 antibodies according to the
manufacturer’s protocol and incubated overnight at 4 8C with 500 lg
HeLa cytoplasmic extracts. Beads were then washed three times with
Na-phosphate buffer [pH 8.0], one time with lysis buffer, and
resuspended in 30 ll of lysis buffer. Aliquots (10 ll) of these beads
were used in each let-7 miRISC cleavage assay.
Live cell imaging, FRET, and immunoﬂuorescence. HeLa cells were
cultured in 35 mm dishes with glass coverslip bottoms (MatTek
Corporation, Ashland, Massachusetts, United States). Expression
vectors for CFP- or YFP-tagged proteins were transfected into cells
using Lipofectamine as described above. 24 h later, the live cells were
monitored for CFP and YFP signals of the transiently expressed
proteins. The signals were detected by a Leica (Wetzlar, Germany)
confocal imaging spectrophotometer system (TCS-SP2) attached to a
Leica DMIRE inverted ﬂuorescence microscope equipped with an
argon laser, two HeNe lasers, an acousto-optic tunable ﬁlter (AOTF)
to attenuate individual visible laser lines, and a tunable acousto-
optical beam splitter (AOBS). A 6331.32 NA oil-immersion objective
was employed. For FRET studies, HeLa cells co-expressing CFP- and
YFP-tagged proteins were ﬁxed with 4% paraformaldehyde in PBS at
room temperature for 20 min and washed three times with PBS. After
the ﬁnal wash, cells were visualized with a Leica confocal imaging
system as described above. FRET experiments were performed by an
acceptor photobleaching method as described [48,49,68]. FRET
efﬁciencies were measured and images were analyzed using Leica
confocal software. For immunoﬂuorescence studies, cells transfected
with Myc-Ago2 were ﬁxed with 4% paraformaldehyde in PBS at room
temperature for 20 min and permeabilized with 0.25% (v/v) Triton X-
100 for 5 min. Samples were washed three times with PBST (0.1% [v/v]
Triton X-100 in PBS) and blocked for 30 min in PBST containing 2%
(w/v) BSA. Primary and secondary antibodies were diluted in blocking
solution during incubation. Secondary antibodies against rabbit IgG,
mouse IgG, and chicken IgY were directly conjugated to Alexa Fluor
dyes (Molecular Probes, Eugene, Oregon, United States). After the
ﬁnal wash, samples were counterstained with Hoechst 33258 to
visualize nuclei with a Leica confocal imaging system as described
above.
In vitro cleavage assay for siRISC and miRISC. HeLa cells
sequentially transfected with siRNAs against P-body components
and EGFP were harvested 24 h after the second transfection.
Cytoplasmic extracts of HeLa cells were prepared as described above
and the protein concentration was determined by Dc protein assay
(Bio-Rad). Target mRNAs were prepared and in vitro cleavage by
GFP-siRISC and let-7-miRISC was assayed as described [53].
Dual ﬂuorescence assay. A dual ﬂuorescence assay was used to
quantify the RNAi activity of siRNAs against GFP. To quantify RNAi
effects, cell lysates were prepared from siRNA-treated cells 24 h post-
transfection. Total cell lysate (150 lg in 200 ll of reporter lysis buffer)
was measured using a Saﬁre plate reader (TECAN). GFP ﬂuorescence
was detected in cell lysates by exciting at 488 nm and recording
emissions from 504–514 nm. The spectrum peak at 509 nm represents
the ﬂuorescence intensity of GFP. RFP ﬂuorescence was detected in
the same cell lysates by exciting at 558 nm and recording emissions
from 578–588 nm. The spectrum peak at 583 nm represents the
ﬂuorescence intensity of RFP. The ﬂuorescence intensity ratio of
target (GFP) to control (RFP) ﬂuorophores was determined in the
presence of siRNA duplexes and normalized to the emissions
measured in mock-treated cells. Normalized ratios , 1.0 indicated
speciﬁc RNA interference.
Incorporation of [
35S]methionine. HeLa cells cultured in 6-well
plates were transfected with siRNAs against RCK/p54 or CDK9
mismatch as a scramble control. 24 h post-transfection, cells were
incubated for 1 h in culture medium lacking methionine and
cysteine, and metabolically labeled by incubating in culture medium
containing 100 lCi/ml Tran
35S-label (MP Biomedicals, Irvine,
California, United States). At 0, 15, 30, 60, and 120 min after
metabolic labeling, cells were washed twice and harvested in 300 llM -
PER buffer (Pierce, Rockford, Illinois, United States) with protease
inhibitors (Sigma). For each experiment, two extra sets of siRNA-
treated cells were trypsinized and counted for total cell numbers. Cell
lysates (50 ll) were incubated with 10 ll of 100% TCA on ice for 30
min, and the protein precipitate was collected on GF/C ﬁlter paper
(Whatman, Clifton, New Jersey, United States), washed with 5 ml of
95% ethanol and counted in scintillation ﬂuid.
Dual luciferase assay for let-7 miRNA-mediated gene silencing. A
dual luciferase assay was used to quantify the effects of let-7- and
RCK/p54-mediated gene silencing on human NRAS or KRAS 39 UTR.
HeLa cells cultured in 6-well plates were co-transfected with 0.8 lg/
well Pp-luc-expressing vectors (pGL3-control, pGL3-NRAS, or pGL3-
KRAS) and with 100 nM let-7-29-O-Me inhibitor or 50 nM siRNA
against RCK/p54. In all experiments, transfection efﬁciencies were
normalized to those of cells co-transfected with the Rr-luc-expressing
vector (pRL-TK; 0.1 lg/well). TCEs were prepared 48 h post-
transfection and dual luciferase assays (Promega, Madison, Wisconsin,
United States) were performed according to the manufacturer’s
protocol and quantiﬁed with a Victor2 multilabel counter (Perkin
Elmer). The Pp-luc/Rr-luc signals were normalized to those from
pGL3-control-transfected cells, showing let-7-regulated gene silencing
of RAS 39 UTR.
siRNA or miRNA luciferase reporter assays. To analyze siRNA- or
miRNA-mediated gene-silencing events, we chose the CXCR4 mRNA
reporter system, in which siRNA- or miRNA-reporter constructs
harbor 1 3 perfectly matched or 4 3 bulged CXCR4 siRNA target
sites, respectively, in the 39 UTR of RL mRNA [56]. HeLa cells
transfected with siRNAs directed against P-body proteins (RCK/p54,
GW182, Lsm1, Ago2) were co-transfected again with siRNA or miRNA
reporters in the absence or presence of 25 nM CXCR4 siRNA. At 24 h
post-transfection, cells were harvested and RL activities were
analyzed. RL signals were normalized to the FL signals from cells
co-transfected with pGL3 plasmid as control.
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Figure S1. Subcellular Localization of Endogenous Ago2 in HeLa
Cells
HeLa cells were analyzed by immunoﬂuorescence using antibodies
against endogenous Ago2 (A) and Lsm1 (B), and stained with
Hoechest 33258 to visualize the nucleus. The images were digitally
merged to indicate co-localization of Ago2 and Lsm1 (C). Arrows
point to P-bodies.
Found at DOI: 10.1371/journal.pbio.0040210.sg001 (4.2 MB TIF).
Figure S2. Speciﬁc Depletion of RCK/p54 in HeLa Cells by RNAi
(A) Speciﬁc knockdown of RCK/p54 in HeLa cells. HeLa cells were
transfected with 50 nM siRNA against RCK/p54, harvested at 24, 48,
and 72 h post-transfection, and TCEs were prepared. Analysis by
immunoblot shows the speciﬁc knockdown of RCK/p54 protein
without changing the protein levels of Lsm1 or Ago2.
(B) Speciﬁc depletion of RCK/p54 mRNA after siRNA treatment.
Total RNA samples (3 lg) from HeLa cells transfected with siRNA
against RCK/p54 were reverse-transcribed and analyzed by quantita-
tive PCR to quantify mRNA levels. RCK/p54 mRNA levels were
normalized to GAPDH mRNA and are presented relative to mock
treatment. Data are from two representative, independent experi-
ments.
Found at DOI: 10.1371/journal.pbio.0040210.sg002 (1.7 MB TIF).
Figure S3. Let-7 Inhibition Does Not Affect RAS mRNA Levels
Total RNA samples (3 lg) from HeLa cells transfected with 100 nM of
let-7 29-O-Me oligonucleotides or 50 nM siRNA against RCK/p54 were
reverse-transcribed and analyzed by quantitative PCR to quantify
mRNA levels. RAS mRNA levels were normalized to GAPDH mRNA
and are presented relative to mock treatment. Data are from two
representative, independent experiments.
Found at DOI: 10.1371/journal.pbio.0040210.sg003 (1.5 MB TIF).
Accession Numbers
The RefSeq (http://www.ncbi.nlm.nih.gov/RefSeq) accession numbers
for the proteins discussed in this paper are Ago1 (NM_012199), Ago2
(NM_012154), Dcp2 (NM_152624), eIF4E (NM_001968), Lsm1
(NM_014462), and RCK/p54 (NM_004397).
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